Pablo Matar

1.6k total citations
37 papers, 1.3k citations indexed

About

Pablo Matar is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Pablo Matar has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 15 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Pablo Matar's work include Immunotherapy and Immune Responses (15 papers), Immune Cell Function and Interaction (14 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Pablo Matar is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), Immune Cell Function and Interaction (14 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Pablo Matar collaborates with scholars based in Argentina, United States and Chile. Pablo Matar's co-authors include O. Graciela Scharovsky, Viviana R. Rozados, Silvia Gervasoni, Federico Rojo, Joaquı́n Arribas, Marta Guzmán, José Baselga, María J. Rico, Mariano F. Zacarías Fluck and Gabriel A. Rabinovich and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Pablo Matar

35 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pablo Matar Argentina 19 673 469 413 308 177 37 1.3k
Justin M. David United States 18 769 1.1× 543 1.2× 558 1.4× 218 0.7× 211 1.2× 30 1.4k
Luigia Stefania Stucci Italy 21 759 1.1× 642 1.4× 482 1.2× 162 0.5× 255 1.4× 46 1.5k
Cinzia Bagalá Italy 18 484 0.7× 629 1.3× 251 0.6× 177 0.6× 198 1.1× 36 1.3k
Masafumi Koshiyama Japan 24 602 0.9× 699 1.5× 400 1.0× 200 0.6× 266 1.5× 81 2.0k
Shailendra K. Gautam United States 18 469 0.7× 543 1.2× 334 0.8× 130 0.4× 165 0.9× 30 1.1k
Meggy Suarez‐Carmona Belgium 16 624 0.9× 509 1.1× 396 1.0× 168 0.5× 331 1.9× 22 1.3k
Audie Rice United States 17 660 1.0× 832 1.8× 334 0.8× 126 0.4× 231 1.3× 28 1.7k
Dennis O. Adeegbe United States 18 845 1.3× 487 1.0× 1.2k 2.9× 232 0.8× 164 0.9× 31 1.9k
Sachi Horibata United States 16 477 0.7× 838 1.8× 550 1.3× 123 0.4× 281 1.6× 31 1.6k
Caterina Ieranò Italy 20 917 1.4× 546 1.2× 462 1.1× 119 0.4× 155 0.9× 34 1.4k

Countries citing papers authored by Pablo Matar

Since Specialization
Citations

This map shows the geographic impact of Pablo Matar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Matar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Matar more than expected).

Fields of papers citing papers by Pablo Matar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Matar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Matar. The network helps show where Pablo Matar may publish in the future.

Co-authorship network of co-authors of Pablo Matar

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Matar. A scholar is included among the top collaborators of Pablo Matar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Matar. Pablo Matar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matar, Pablo, Amjad Kanaan, Assaad A. Eid, et al.. (2025). GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis. Frontiers in Endocrinology. 16. 1627909–1627909.
2.
Matar, Pablo. (2022). Biosimilarity is not a transitive property: implication for interchangeability, naming and pharmacovigilance. Generics and Biosimilars Initiative Journal. 11(1). 36–40. 2 indexed citations
3.
Malvicini, Mariana, Esteban Fiore, Flavia Piccioni, et al.. (2015). Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. Molecular Therapy. 23(9). 1444–1455. 22 indexed citations
4.
Malvicini, Mariana, Flavia Piccioni, Juan Bayo, et al.. (2012). Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide. OncoImmunology. 1(9). 1626–1628. 3 indexed citations
5.
Malvicini, Mariana, Mariana Ingolotti, Flavia Piccioni, et al.. (2011). Reversal of gastrointestinal carcinoma‐induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL‐12. Molecular Oncology. 5(3). 242–255. 26 indexed citations
6.
Rozados, Viviana R., et al.. (2009). The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 18(11). 601–605. 27 indexed citations
7.
Matar, Pablo, Laura Alaniz, Viviana R. Rozados, et al.. (2009). Immunotherapy for liver tumors: present status and future prospects. Journal of Biomedical Science. 16(1). 30–30. 22 indexed citations
8.
Alaniz, Laura, Mariana Malvicini, Diego M. Avella, et al.. (2009). Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Letters. 278(1). 9–16. 55 indexed citations
9.
Croci, Diego O., Mariano F. Zacarías Fluck, María J. Rico, et al.. (2007). Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunology Immunotherapy. 56(11). 1687–1700. 182 indexed citations
10.
Rico, María J., Pablo Matar, Silvia Gervasoni, et al.. (2005). The transition to the metastatic phenotype of rat lymphoma cells involves up-regulation of IL-10 receptor expression and IL-10 secretion. Clinical & Experimental Metastasis. 22(2). 127–135. 6 indexed citations
11.
Rozados, V. R., et al.. (2004). Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Annals of Oncology. 15(10). 1543–1550. 43 indexed citations
12.
Anido, Judit, Pablo Matar, Joan Albanell, et al.. (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.. PubMed. 9(4). 1274–83. 213 indexed citations
13.
Ciocca, Daniel R., et al.. (2003). Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress and Chaperones. 8(1). 26–26. 41 indexed citations
14.
Matar, Pablo, et al.. (2002). Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunology Immunotherapy. 50(11). 588–596. 98 indexed citations
15.
Rabinovich, Gabriel A., et al.. (2002). The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunology Immunotherapy. 50(11). 597–603. 26 indexed citations
16.
Matar, Pablo, Viviana R. Rozados, Silvia Gervasoni, & O. Graciela Scharovsky. (2001). Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. International Immunopharmacology. 1(2). 307–319. 43 indexed citations
17.
Matar, Pablo, et al.. (2000). Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. European Journal of Cancer. 36(8). 1060–1066. 39 indexed citations
18.
Scharovsky, O. Graciela, Viviana R. Rozados, Silvia Gervasoni, & Pablo Matar. (2000). Inhibition ofras oncogene: A novel approach to antineoplastic therapy. Journal of Biomedical Science. 7(4). 292–298. 34 indexed citations
19.
Matar, Pablo, et al.. (1999). Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clinical & Experimental Metastasis. 17(1). 25–32. 42 indexed citations
20.
Matar, Pablo, Viviana R. Rozados, Eduardo Roggero, R. Daniel Bonfil, & O. Graciela Scharovsky. (1998). Modulation of the Antimetastatic Effect of a Single Low Dose of Cyclophosphamide on Rat Lymphoma. Tumor Biology. 19(2). 69–76. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justin M. David Breakdown of academic impact, for papers by Luigia Stefania Stucci Breakdown of academic impact, for papers by Cinzia Bagalá Breakdown of academic impact, for papers by Masafumi Koshiyama Breakdown of academic impact, for papers by Shailendra K. Gautam Breakdown of academic impact, for papers by Meggy Suarez‐Carmona Breakdown of academic impact, for papers by Audie Rice Breakdown of academic impact, for papers by Dennis O. Adeegbe Breakdown of academic impact, for papers by Sachi Horibata Breakdown of academic impact, for papers by Caterina Ieranò
Rankless by CCL
2026